HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendices All Versions of this Article: thx.2006.069872v1 thx.2006.069872v2 62/8/690    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertino, P. Articles by Mutti, L. Search for Related Content PubMed PubMed Citation Articles by Bertino, P. Articles by Mutti, L.

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

¹ DISCAFF Department and DFB Center, University of Piemonte Orientale "A Avogadro", Novara, Italy
² Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy
³ Chest Medicine Unit, Brescia Hospital, Brescia, Italy
⁴ National Cancer Institute, Genoa, Italy
⁵ Local Health Unit, 11 Piemonte, Italy

Correspondence to:
Correspondence to:
Dr Giovanni Gaudino
DISCAFF Department and DFBC Center, University of Piemonte Orientale"A Avogadro", 28100 Novara, Italy; giovanni.gaudino{at}unipmn.it

Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor ß (PDGFRß). PDGFRß is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma.

Methods: Cultures from mesothelioma MMP, REN and ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent.

Results: Imatinib induced cytotoxicity and apoptosis selectively on PDGFRß positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed.

Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.

Abbreviations: HGF, hepatocyte growth factor; HMC, human mesothelial cells; LC₅₀, lethal concentration killing 50% of cells; M-CSF, macrophage colony stimulating factor; MMe, malignant mesothelioma; PDGF, platelet derived growth factor; PDGFRß, PDGF receptor ß; VEGF, vascular endothelial growth factor

This article has been cited by other articles:

				P. Bertino, F. Piccardi, C. Porta, R. Favoni, M. Cilli, L. Mutti, and G. Gaudino Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts Clin. Cancer Res., January 15, 2008; 14(2): 541 - 548. [Abstract] [Full Text] [PDF]